Answer
Kymriah (tisagenlecleucel) is contraindicated in patients with hypersensitivity to the active substance or any excipient listed in section 6.1.
Sources for this answer
- Kymriah cells dispersion for infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.3 Contraindications · Version 15Document updated
Sources checked